八珍化积汤联合卡瑞利珠单抗治疗晚期食管癌的临床效果  

Clinical Efficacy of Bazhen Huaji Decoction Combined with Camrelizumab in the Treatment of Advanced Esophageal Cancer

作　　者：朱淑青 张涛 王金云 Zhu Shuqing;Zhang Tao;Wang Jinyun(Department of Oncology Nutrition,Hefei Cancer Hospital,Chinese Academy of Sciences,Hefei 230031,China;Department of Oncology,West District,Anhui Provincial Hospital of Traditional Chinese Medicine,Hefei 230031,China)

机构地区：[1]中国科学院合肥肿瘤医院肿瘤营养治疗科,安徽合肥230031 [2]安徽省中医院西区肿瘤科,安徽合肥230031

出　　处：《中医药学报》2025年第1期77-82,共6页Acta Chinese Medicine and Pharmacology

基　　金：安徽省自然科学基金项目(2008085MH245)。

摘　　要：目的:探讨八珍化积汤联合卡瑞利珠单抗治疗晚期食管癌的临床效果。方法:回顾性分析2022年5月-2023年7月于中国科学院合肥肿瘤医院和安徽省中医院西区就诊的104例晚期食管癌患者临床资料,依据治疗方法分组,其中52例采用卡瑞利珠单抗治疗,纳入常规组,52例采用八珍化积汤联合卡瑞利珠单抗治疗,纳入联合组。对比两组患者的中医证候积分、血清程序性死亡受体1(PD-1)、程序性死亡受体配体(PD-L1)、鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)、卡氏功能状态(KPS)评分、T细胞亚群CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、树突状细胞(DC)、临床疗效、不良反应发生情况。结果:治疗后,联合组患者中医证候积分低于常规组(P<0.01);联合组PD-1、PD-L1水平低于常规组(P<0.01);联合组SCC-Ag及CEA水平均低于常规组(P<0.01);联合组KPS评分高于常规组(P<0.01);联合组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、DC水平均高于常规组(P<0.05);联合组患者治疗总有效率高于常规组(P<0.05);两组1~2级不良反应总发生率差异无统计学意义(P>0.05)。结论:八珍化积汤联合卡瑞利珠单抗能够改善晚期食管癌患者血清学指标及肿瘤标志物水平,降低中医证候积分,提高患者免疫功能及临床疗效,延长患者生存期,安全性较高。Objective:To investigate the clinical efficacy of Bazhen Huaji Decoction combined with camrelizumab in the treatment of advanced esophageal cancer.Methods:A retrospective analysis was conducted on the clinical data of 104 patients with advanced esophageal cancer who were treated between May 2022 and July 2023 at Hefei Cancer Hospital of the Chinese Academy of Sciences and the West District of Anhui Provincial Hospital of Traditional Chinese Medicine.Patients were divided into groups according to treatment method:52 patients receiving camrelizumab alone were classified as the routine group,and 52 patients receiving Bazhen Huaji Decoction combined with camrelizumab were classified as the combination group.The groups were compared in terms of Traditional Chinese Medicine(TCM)syndrome scores,serum levels of programmed death receptor 1(PD-1),programmed death ligand 1(PD-L1),squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA),Karnofsky Performance Status(KPS)scores,T-cell subsets CD3^(+),CD4^(+),CD4^(+)/CD8^(+),dendritic cells(DC),clinical efficacy,and incidence of adverse reactions.Results:After treatment,TCM syndrome scores in the combination group were lower than those in the routine group(P<0.01);PD-1 and PD-L1 levels in the combination group were also lower(P<0.01);SCC-Ag and CEA levels in the combination group were lower than in the routine group(P<0.05);KPS scores were higher in the combination group(P<0.01);CD3^(+),CD4^(+),CD4^(+)/CD8^(+),and DC levels in the combination group were higher than in the routine group(P<0.01);and the overall effective rate of treatment in the combination group was higher than that in the routine group(P<0.05).There was no statistically significant difference in the total incidence of grade 1-2 adverse reactions between the groups(P>0.05).Conclusion:Bazhen Huaji Decoction combined with camrelizumab can improve serum indicators and tumor marker levels in patients with advanced esophageal cancer,reduce TCM syndrome scores,enhance immune function,improve clinical effi

关 键 词：八珍化积汤 晚期食管癌 中医证候积分 免疫功能 临床疗效 不良反应 

分 类 号：R256.32[医药卫生—中医内科学]